[Recurrent corneal keratitis associated with the use of latanoprost].
Asensio Sánchez
V M
VM
D000212:Acyclovir / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005901:Glaucoma / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007408:Intestinal Absorption; D016849:Keratitis, Herpetic / Q000139:chemically induced / Q000188:drug therapy*; D000077338:Latanoprost; D011453:Prostaglandins / Q000502:physiology; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects* / Q000494:pharmacology; D012008:Recurrence; D018139:Simplexvirus / Q000187:drug effects* / Q000502:physiology; D000077483:Valacyclovir; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D014775:Virus Activation / Q000187:drug effects*
D000319:Adrenergic beta-Antagonists; D000998:Antiviral Agents; D011453:Prostaglandins; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir